Nuclear Medicine & Radiopharmaceuticals

We Help Nuclear Medicine and Radiopharmaceutical Companies

Amplify Your Insights

Deeper understanding leads to consistency.

AIQ Solutions is a vital partner within the radiopharmaceuticals space.
Learn More
Information on this page is intended for research use only. Not all applications and/or claims listed are currently cleared for use in treatment of patients. TRAQinform IQ software has been cleared by the FDA for clinical use under 510(k) K173444.

Every person is different. Every disease is different. Every lesion is different.

AIQ has solutions

With the AIQ collaborative workflow, the steps are customizable to meet the specific requirements for clinical studies.

Benefit 01—

Consistent and Comprehensive Tracer Uptake Assessment from each lesion and organ

AI-driven algorithms allow for reproducible and repeatable imaging analysis, eliminating inter- and intra-physician variability.

Learn more
Text Link

Full Poster: Automated Segmentation and Quantitation of PET/CT Images Using 124I-p5+14 (AT-01) in Patients with AL and ATTR Amyloidosis

Benefit 02—

Quantification of longitudinal tracer changes

TRAQinform TR technology matches every lesion or organ across scans and quantifies changes in tracer uptake with high sensitivity and specificity.

Learn more
Text Link

Additional data: AI ASSISTED WHOLE BODY ASSESSMENT OF IMMUNOTHERAPY RESPONSE USING [ 18 F]F ARAG , A PET AGENT FOR ACTIVATED T CELLS

Benefit 03—

Determination of Tracer Concordance

Enhanced capabilities allow for custom models to compare tracer uptake between multiple radiotracers for each organ and lesion. AIQ Solutions quantifies and characterizes tracer uptake for each individual lesion as well as individual organ and determines correlation with clinical outcomes.

Learn more
Click to see full poster

Tracer concordance technologies: Bio-distribution patterns of tracers within segmented organs and individual lesions.

Benefit 04—

Analysis of Tracer Bio Distribution Patterns

Spatiotemporal analysis reveals heterogeneity in the signal range between different patients and between different regions of interest within the same patient.

Learn more
Click for full poster

Bio distribution of  AT-01 in a representative healthy subject (A) and patient with systemic AL amyloidosis (B). Maximum intensity projection and coronal views in (A) show physiologic uptake was observed in the parotid, salivary and thyroid glands, as well as saliva, stomach lumen, urine in ureters, and bladder. No myocardial uptake was observed. Click to view full poster

A valued partner for your studies

AIQ Collaboration

AIQ's collaboration consist of a workflow that is simple and easy to implement with no interruptions. We pride ourselves on building a partnership that up holds our company's values and value proposition. These workflows work whether you are running a single or multi-site study. We also partner with CROs to acquire imaging data.
Contact Us

What questions do you have?

Drop us a line and learn more about AIQ Solutions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Revolutionizing the understanding of treatment response to improve patient outcomes
© Copyright 2022 AIQ Global Inc.
Website by Acumium

Australian Privacy Policy
AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K173444